| Full Name | Tia Zutter |
|---|---|
| Gender | Female |
| Speciality | Registered Nurse |
| Location | 41632 206th St, Iroquois, South Dakota |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770252579 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 163W00000X | Registered Nurse | R055121 (South Dakota) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Tia Zutter, 41632 206th St, Iroquois, SD 57353-6716 Ph: (605) 290-4385 | Tia Zutter, 41632 206th St, Iroquois, SD 57353-6716 Ph: (605) 290-4385 |
News Archive
Initial results of a multicenter study coordinated by researchers at Fred Hutchinson Cancer Research Center indicates that two investigational urine-based biomarkers are associated with prostate cancers that are likely to be aggressive and potentially life-threatening among men who take a "watchful waiting," or active-surveillance approach to manage their disease.
Sabril (vigabatrin) Oral Solution has been approved by the U.S. Food and Drug Administration to treat infantile spasms in children ages 1 month to 2 years. Sabril is the first drug in the United States approved to treat the disorder, characterized by a severe type of seizure that usually appears in the first year of life, typically between ages 4 months and 8 months.
Itamar Medical announced confirmation of PAT technology by several prestigious research groups. In light of scientific confirmation of PAT technology, Itamar Medical will now promote clinical use in the medical community for the prevention of cardiovascular disease.
If people are unable to perceive their own errors as they complete a routine, simple task, their skill will decline over time, Johns Hopkins researchers have found - but not for the reasons scientists assumed.
Researchers at The University of Texas MD Anderson Cancer Center have discovered that triple negative breast cancer cells can develop resistance to frontline, or neoadjuvant, chemotherapy not by acquiring permanent adaptations, but rather transiently turning on molecular pathways that protect the cells.
› Verified 5 days ago